Posted by Michael Wonder on 15 May 2017
TC publishes opinion on Pfizer's Ibrance
11 May 2017 - The Commission considers that the medical service rendered by palbociclib when used in combination with letrozole or fulvestrant in women who have been previously treated with hormone therapy for the treatment of post-menopausal women with locally advanced or metastatic breast cancer without short-term life threatening symptomatic visceral involvement is important.
The Commission considers that palbocilib provides a minor improvement medical benefit (ASMR IV) compared to letrozole or fulvestrant in the management of advanced breast cancer in post-menopausal women.
